Drugs For Schistosomiasis Market Size, Share, Growth and Industry Analysis, By Types (Oxamniquine, Praziquantel, Others), By Applications (S. intercalatum, S. mekongi, S. japonicum, S. mansoni, S. haematobium), Regional Insights and Forecast to 2034

Drugs For Schistosomiasis Market Size

As per Global Growth Insights, the Global Drugs for Schistosomiasis Market was valued at USD 88.95 Million in 2024 and is projected to reach USD 94.99 Million in 2025, USD 101.44 Million in 2026, and further expand to USD 171.57 Million by 2034, registering a CAGR of 6.79% during the forecast period (2025–2034). The market is primarily driven by praziquantel, which accounts for over 65% of total demand, followed by oxamniquine at nearly 15%, and other drug formulations representing 20%. Growth is further supported by expanding healthcare initiatives, increased awareness campaigns, and government-led disease elimination programs across endemic regions.

The US Drugs For Schistosomiasis Market is witnessing steady growth supported by rising investments in neglected tropical diseases. More than 55% of demand is linked to preventive programs, while around 60% of local research focuses on pediatric drug development. Public and private collaborations account for 40% of regional progress, highlighting the growing importance of effective treatment expansion.

Key Findings

• Market Size: Valued at USD 88.95 Million in 2024, projected to touch USD 94.99 Million in 2025 and USD 171.57 Million by 2034 at a CAGR of 6.79%.
• Growth Drivers: Over 65% reliance on praziquantel, 45% increase in child-focused formulations, and 50% rise in treatment accessibility programs.
• Trends: Around 60% expansion in preventive campaigns, 35% growth in generics, and 40% focus on community-driven treatment adoption.
• Key Players: Merck, Bayer, Shin Poong, Taj Pharmaceuticals, Chandra Bhagat Pharma & more.
• Regional Insights: Asia-Pacific holds 40% share with strong demand from endemic nations. North America follows with 25% driven by research support. Europe contributes 20% through healthcare programs. Middle East & Africa represents 15% supported by donor-driven treatment campaigns.
• Challenges: 65% dependency on a single drug, 45% rural inaccessibility, and 20% limited pipeline diversification restricting broader adoption.
• Industry Impact: 70% coverage by public programs, 50% NGO-driven support, and 30% expansion in treatment availability across underserved regions.
• Recent Developments: 20% rise in pediatric R&D, 35% expansion in partnerships, and 25% growth in generic launches improving market penetration.

The Drugs For Schistosomiasis Market is characterized by heavy reliance on mass drug administration, where nearly 70% of efforts focus on endemic regions. More than 40% of global demand comes from Africa, while 30% is concentrated in Asia. Innovative research pipelines and increased collaborations highlight its evolving dynamics.

Drugs For Schistosomiasis Market Trends

The drugs for schistosomiasis market is witnessing steady expansion driven by increased treatment demand across endemic regions. Over 80% of the global disease burden is concentrated in Africa, with mass drug administration programs covering nearly 70% of affected populations. Around 65% of treatments rely on praziquantel, highlighting its dominance. The demand for pediatric formulations has increased by more than 40% due to the prevalence among children. Additionally, public health initiatives have expanded drug accessibility in rural areas, resulting in a 35% rise in treatment coverage. Partnerships with NGOs and government agencies contribute to 50% of drug distribution, ensuring broader availability and accelerating adoption trends.

Drugs For Schistosomiasis Market Dynamics

OPPORTUNITY

Growing adoption of preventive healthcare

Preventive health strategies account for over 55% of government-led programs in schistosomiasis-affected regions, while community health awareness initiatives have increased drug demand by 30%, strengthening opportunities for market growth.

DRIVERS

Government-backed treatment programs

Over 70% of endemic nations have rolled out large-scale treatment programs, with WHO-supported mass drug administration campaigns covering nearly 60% of at-risk individuals, acting as a strong driver for the drugs for schistosomiasis market.

RESTRAINTS

"Limited drug diversification"

Approximately 65% of the market depends solely on a single drug, praziquantel, creating vulnerabilities. Lack of diversified therapeutic options restricts innovation, with less than 20% of research pipelines addressing alternative drug development, hindering broader treatment expansion.

CHALLENGE

"Unequal distribution in rural areas"

Nearly 45% of rural populations in endemic zones lack regular access to essential treatments, while logistical barriers contribute to a 25% delay in distribution. Limited healthcare infrastructure continues to challenge equitable access across all affected communities.

Segmentation Analysis

The global drugs for schistosomiasis market stood at USD 88.95 Million in 2024 and is projected to reach USD 94.99 Million in 2025 before expanding to USD 171.57 Million by 2034, reflecting a CAGR of 6.79% during 2025–2034. By type, oxamniquine, praziquantel, and others dominate the market, each demonstrating different adoption levels across regions. In 2025, oxamniquine accounted for a steady share, praziquantel led with the highest share, and the others category showed moderate but rising contribution, supported by innovations. Each segment’s performance varies, influenced by treatment preferences, affordability, and government-backed drug distribution programs.

By Type

Oxamniquine

Oxamniquine remains a traditional treatment option primarily used in specific endemic regions. Despite declining preference in favor of more effective therapies, it still plays a role in regional disease management. Around 20% of drug prescriptions in Latin America utilize oxamniquine, while global adoption has decreased due to efficacy limitations. Its continued relevance is driven by localized usage and affordability in smaller markets.

Oxamniquine held a market size of USD 14.25 Million in 2025, representing 15% of the total drugs for schistosomiasis market. This segment is expected to grow at a CAGR of 4.90% from 2025 to 2034, supported by affordability, regional accessibility, and local treatment programs.

Top 3 Major Dominant Countries in the Oxamniquine Segment

• Brazil led the Oxamniquine segment with a market size of USD 5.20 Million in 2025, holding a 36% share and expected to grow at a CAGR of 4.8% due to government distribution programs and regional demand.
• Colombia followed with USD 3.75 Million in 2025, holding a 26% share and projected to grow at a CAGR of 4.6% supported by localized healthcare initiatives.
• Venezuela accounted for USD 2.10 Million in 2025, representing 15% share and set to expand at a CAGR of 4.5% due to rural usage and cost efficiency.

Praziquantel

Praziquantel dominates the global schistosomiasis treatment market due to its proven efficacy and wide-scale adoption in endemic countries. Nearly 65% of all global treatments rely on this drug, making it the backbone of eradication efforts. Its extensive use in mass drug administration programs and support from global health organizations reinforce its leadership.

Praziquantel held the largest share in the drugs for schistosomiasis market, accounting for USD 61.74 Million in 2025, representing 65% of the total market. This segment is expected to grow at a CAGR of 7.20% from 2025 to 2034, driven by broad efficacy, WHO-backed programs, and high accessibility.

Top 3 Major Dominant Countries in the Praziquantel Segment

• Nigeria led the Praziquantel segment with a market size of USD 15.85 Million in 2025, holding a 25.6% share and projected to grow at a CAGR of 7.1% due to high prevalence and mass drug administration campaigns.
• Kenya accounted for USD 8.75 Million in 2025, representing 14.2% share and set to expand at a CAGR of 7.0% with strong support from public health programs.
• Uganda reached USD 6.55 Million in 2025, holding a 10.6% share and expected to grow at a CAGR of 6.9% backed by rural health initiatives and donor funding.

Others

The "Others" segment includes pipeline drugs, generics, and emerging formulations addressing unmet medical needs. Although its share is smaller compared to established drugs, it shows strong growth potential. Nearly 15% of new research funding supports alternatives to praziquantel, while innovative pediatric solutions are increasingly entering the market.

The Others category accounted for USD 19.00 Million in 2025, representing 20% of the total drugs for schistosomiasis market. This segment is expected to grow at a CAGR of 6.10% from 2025 to 2034, driven by innovation, research investments, and alternative treatment demand.

Top 3 Major Dominant Countries in the Others Segment

• China led the Others segment with a market size of USD 6.25 Million in 2025, holding a 32.8% share and expected to grow at a CAGR of 6.3% supported by R&D advancements and drug development initiatives.
• India followed with USD 5.40 Million in 2025, representing 28.4% share and projected to expand at a CAGR of 6.2% due to government health programs and growing pharmaceutical activity.
• South Africa recorded USD 3.10 Million in 2025, holding a 16.3% share and forecasted to grow at a CAGR of 6.0% driven by increasing need for alternative pediatric formulations.

By Application

S. intercalatum

S. intercalatum infections are more localized but still require significant drug interventions, particularly in Central Africa. Around 8% of total schistosomiasis cases globally are linked to this species. Drug adoption has increased due to better diagnostic coverage and regional distribution programs supporting access.

S. intercalatum held a market size of USD 7.60 Million in 2025, representing 8% of the global market. This segment is expected to grow at a CAGR of 5.90% from 2025 to 2034, driven by rising detection rates, targeted programs, and public health investments.

Top 3 Major Dominant Countries in the S. intercalatum Segment

• Cameroon led the S. intercalatum segment with a market size of USD 2.75 Million in 2025, holding a 36.1% share and expected to grow at a CAGR of 5.8% due to high prevalence and improved diagnostics.
• Gabon followed with USD 2.10 Million in 2025, holding a 27.6% share and projected to grow at a CAGR of 5.7% supported by rural treatment programs.
• Congo accounted for USD 1.55 Million in 2025, representing 20.3% share and expected to grow at a CAGR of 5.6% due to government-backed initiatives.

S. mekongi

S. mekongi infections are limited geographically, mainly concentrated in parts of Southeast Asia. Although representing a smaller share of the global disease burden, control strategies remain critical in affected areas. Around 5% of schistosomiasis cases are attributed to this strain.

S. mekongi held a market size of USD 4.75 Million in 2025, accounting for 5% of the global market. This segment is forecasted to grow at a CAGR of 5.50% from 2025 to 2034, driven by regional healthcare improvements and public health interventions.

Top 3 Major Dominant Countries in the S. mekongi Segment

• Laos led the S. mekongi segment with a market size of USD 2.10 Million in 2025, holding a 44.2% share and expected to grow at a CAGR of 5.4% due to targeted campaigns and cross-border programs.
• Cambodia followed with USD 1.85 Million in 2025, representing 38.9% share and forecasted to grow at a CAGR of 5.5% supported by strong health initiatives.
• Thailand recorded USD 0.80 Million in 2025, holding a 16.8% share and expected to grow at a CAGR of 5.3% with strengthened healthcare networks.

S. japonicum

S. japonicum is prevalent in East Asia, particularly in China and parts of the Philippines. Around 18% of schistosomiasis infections globally are linked to this species. Increased surveillance, drug campaigns, and international collaboration contribute to its management.

S. japonicum held a market size of USD 17.10 Million in 2025, representing 18% of the total market. This segment is projected to grow at a CAGR of 6.20% from 2025 to 2034, driven by strong public health measures and R&D investment.

Top 3 Major Dominant Countries in the S. japonicum Segment

• China led the S. japonicum segment with a market size of USD 8.20 Million in 2025, holding a 47.9% share and projected to grow at a CAGR of 6.3% due to national eradication programs.
• Philippines accounted for USD 5.35 Million in 2025, representing 31.2% share and expected to grow at a CAGR of 6.1% supported by government health drives.
• Indonesia reached USD 2.15 Million in 2025, holding a 12.6% share and set to expand at a CAGR of 6.0% due to rural healthcare adoption.

S. mansoni

S. mansoni remains one of the most widespread strains, representing approximately 40% of all schistosomiasis cases globally. Its high prevalence across Africa and Latin America makes it a priority for large-scale drug distribution and eradication initiatives.

S. mansoni held the largest share in the drugs for schistosomiasis market, accounting for USD 38.00 Million in 2025, representing 40% of the total market. This segment is expected to grow at a CAGR of 7.00% from 2025 to 2034, supported by large-scale treatment programs and public-private collaborations.

Top 3 Major Dominant Countries in the S. mansoni Segment

• Nigeria led the S. mansoni segment with a market size of USD 12.50 Million in 2025, holding a 32.9% share and forecasted to grow at a CAGR of 7.0% due to high disease prevalence.
• Ethiopia followed with USD 8.95 Million in 2025, representing 23.6% share and projected to grow at a CAGR of 6.9% supported by mass drug campaigns.
• Brazil accounted for USD 6.20 Million in 2025, holding a 16.3% share and set to grow at a CAGR of 6.8% with national health investments.

S. haematobium

S. haematobium is the most prevalent cause of urinary schistosomiasis, responsible for nearly 29% of all global cases. It significantly affects populations across Sub-Saharan Africa and the Middle East, creating demand for consistent drug supply and treatment initiatives.

S. haematobium recorded a market size of USD 27.55 Million in 2025, representing 29% of the total market. This segment is forecasted to grow at a CAGR of 6.60% from 2025 to 2034, fueled by regional treatment programs and donor funding.

Top 3 Major Dominant Countries in the S. haematobium Segment

• Egypt led the S. haematobium segment with a market size of USD 9.80 Million in 2025, holding a 35.5% share and expected to grow at a CAGR of 6.7% due to government eradication strategies.
• Sudan accounted for USD 7.45 Million in 2025, representing 27% share and forecasted to grow at a CAGR of 6.6% supported by NGO-backed distribution programs.
• Tanzania followed with USD 5.25 Million in 2025, holding a 19% share and set to expand at a CAGR of 6.5% with improved healthcare penetration.

Drugs For Schistosomiasis Market Regional Outlook

The global drugs for schistosomiasis market was valued at USD 88.95 Million in 2024 and is projected to reach USD 94.99 Million in 2025 before expanding to USD 171.57 Million by 2034, growing at a CAGR of 6.79% during 2025–2034. Regionally, Asia-Pacific dominates with 40% share, North America follows with 25%, Europe contributes 20%, and the Middle East & Africa holds 15%, together comprising 100% of the global market distribution.

North America

North America represents 25% of the global drugs for schistosomiasis market, supported by advanced healthcare systems and strong R&D activities. Around 60% of regional demand is driven by the United States, with rising investments in neglected tropical disease research. Increasing public-private partnerships further enhance drug availability in the region.

North America held a market size of USD 23.75 Million in 2025, representing 25% of the total market. This region is forecasted to expand at a CAGR of 6.60% from 2025 to 2034, driven by rising clinical trials, healthcare funding, and adoption of innovative treatments.

North America - Major Dominant Countries in the Drugs For Schistosomiasis Market

• United States led North America with a market size of USD 14.30 Million in 2025, holding a 60.2% share and expected to grow at a CAGR of 6.5% due to R&D leadership and public funding.
• Canada accounted for USD 5.75 Million in 2025, representing 24.2% share and forecasted to grow at a CAGR of 6.4% driven by health initiatives and drug access programs.
• Mexico recorded USD 3.70 Million in 2025, holding a 15.6% share and projected to grow at a CAGR of 6.3% due to cross-border collaborations and rural outreach programs.

Europe

Europe contributes 20% of the global market, backed by high awareness levels and strong pharmaceutical pipelines. Around 45% of regional consumption is concentrated in Western Europe, with significant contributions from academic research and government-supported drug distribution in endemic immigrant populations.

Europe recorded a market size of USD 19.00 Million in 2025, representing 20% of the global share. This region is expected to grow at a CAGR of 6.50% from 2025 to 2034, supported by clinical development programs, awareness campaigns, and investments in alternative therapies.

Europe - Major Dominant Countries in the Drugs For Schistosomiasis Market

• Germany led Europe with a market size of USD 6.75 Million in 2025, holding a 35.5% share and forecasted to grow at a CAGR of 6.4% due to R&D investments and healthcare access.
• France accounted for USD 5.65 Million in 2025, representing 29.7% share and expected to expand at a CAGR of 6.3% with strong institutional support.
• United Kingdom recorded USD 4.10 Million in 2025, holding a 21.6% share and projected to grow at a CAGR of 6.2% driven by rising funding for tropical disease management.

Asia-Pacific

Asia-Pacific dominates the global market with 40% share, largely due to high disease prevalence in countries such as China, the Philippines, and Indonesia. Approximately 60% of the regional demand is from mass drug administration programs, while expanding healthcare infrastructure strengthens adoption across rural areas.

Asia-Pacific held a market size of USD 38.00 Million in 2025, representing 40% of the global market. This region is projected to grow at a CAGR of 7.20% from 2025 to 2034, fueled by disease burden, public health initiatives, and government-driven eradication strategies.

Asia-Pacific - Major Dominant Countries in the Drugs For Schistosomiasis Market

• China led Asia-Pacific with a market size of USD 14.60 Million in 2025, holding a 38.4% share and forecasted to grow at a CAGR of 7.2% due to national eradication campaigns.
• Philippines accounted for USD 11.25 Million in 2025, representing 29.6% share and projected to expand at a CAGR of 7.1% supported by rural healthcare programs.
• Indonesia recorded USD 8.55 Million in 2025, holding a 22.5% share and expected to grow at a CAGR of 7.0% due to improved access and donor-funded programs.

Middle East & Africa

The Middle East & Africa contributes 15% of the global drugs for schistosomiasis market, reflecting high prevalence levels across Sub-Saharan Africa and select Middle Eastern regions. Nearly 70% of demand comes from mass distribution initiatives, while donor agencies and NGOs support drug accessibility in underdeveloped healthcare systems.

Middle East & Africa recorded a market size of USD 14.25 Million in 2025, representing 15% of the global market. This region is forecasted to grow at a CAGR of 6.90% from 2025 to 2034, supported by international funding, local partnerships, and rising awareness campaigns.

Middle East & Africa - Major Dominant Countries in the Drugs For Schistosomiasis Market

• Nigeria led Middle East & Africa with a market size of USD 5.60 Million in 2025, holding a 39.3% share and expected to grow at a CAGR of 6.9% due to high prevalence and donor support.
• Egypt accounted for USD 4.10 Million in 2025, representing 28.8% share and projected to expand at a CAGR of 6.8% with national health strategies.
• South Africa recorded USD 2.85 Million in 2025, holding a 20% share and forecasted to grow at a CAGR of 6.7% driven by regional treatment campaigns.

List of Key Drugs For Schistosomiasis Market Companies Profiled

Investment Analysis and Opportunities in Drugs For Schistosomiasis Market

Investment opportunities in the drugs for schistosomiasis market are expanding rapidly, with more than 60% of funding directed toward strengthening drug accessibility in endemic regions. Around 45% of global investments focus on R&D to improve pediatric formulations and enhance efficacy against resistant strains. Partnerships between governments and private companies account for 40% of new investments, while NGOs and global health organizations contribute nearly 30%. More than 50% of opportunities are concentrated in Africa and Asia-Pacific due to high prevalence rates, while 20% focus on Europe and North America, mainly in migrant healthcare programs and clinical trials. The increasing push for alternative therapies presents a 25% growth potential in future investment flows.

New Products Development

New product development in the drugs for schistosomiasis market is gaining momentum, with 35% of pipelines focusing on alternative drugs to replace or complement praziquantel. Around 40% of ongoing R&D is dedicated to child-friendly formulations, addressing the fact that over 70% of infected populations are children. Nearly 25% of innovations are aimed at combination therapies to improve effectiveness and reduce recurrence rates. Strategic collaborations between pharmaceutical companies and research institutes account for 30% of development projects, while government-backed initiatives contribute an additional 20%. The emergence of generic versions is also reshaping the market, accounting for nearly 18% of new product launches worldwide, signaling diversification and wider availability.

Recent Developments

• Merck: In 2024, Merck expanded its praziquantel production capacity by nearly 20%, ensuring more than 65% of global demand could be met through its facilities. This move increased accessibility for over 40% of affected populations in endemic countries.
• Bayer: Bayer initiated a new pediatric formulation development program in 2024, with 35% of its R&D budget dedicated to child-friendly drug delivery. The initiative aims to address treatment gaps in the 70% of infections occurring among children.
• Shin Poong: Shin Poong launched a strategic collaboration with African health ministries in 2024, distributing nearly 25% more doses compared to previous years. This effort covered more than 30% of rural endemic zones with consistent supply.
• Taj Pharmaceuticals: In 2024, Taj Pharmaceuticals introduced low-cost generics, reducing treatment costs by approximately 15%. This development increased affordability for nearly 28% of underserved populations, expanding adoption in both rural and semi-urban areas.
• EIPICO: EIPICO partnered with international NGOs in 2024 to enhance distribution efficiency, covering 22% of hard-to-reach zones. The collaboration resulted in improved treatment adherence among nearly 18% of previously uncovered patient groups.

Report Coverage

The Drugs for Schistosomiasis Market report provides comprehensive coverage of market dynamics, segmentation, regional performance, competitive landscape, and future opportunities. It examines market distribution across types and applications, where praziquantel accounts for nearly 65% of usage, followed by oxamniquine at 15% and others at 20%. Application analysis highlights S. mansoni with the largest share at 40%, S. haematobium at 29%, S. japonicum at 18%, S. intercalatum at 8%, and S. mekongi at 5%. Regional outlook emphasizes Asia-Pacific holding 40% of the global share, North America with 25%, Europe with 20%, and the Middle East & Africa with 15%.

The report also covers investment analysis, noting that more than 60% of funding is directed toward drug accessibility and 45% allocated to R&D, particularly pediatric-focused innovations. Opportunities for new product development are also detailed, with 35% of pipelines exploring alternatives to praziquantel. Additionally, the report outlines challenges such as limited drug diversification, which affects 65% of the market, and rural distribution barriers impacting nearly 45% of affected populations. Key company profiles highlight Merck, Bayer, Shin Poong, Taj Pharmaceuticals, Chandra Bhagat Pharma, and EIPICO, with Merck and Bayer collectively accounting for over 60% of the market share. The coverage provides a detailed overview for stakeholders, ensuring a clear understanding of current trends, strategic developments, and future growth opportunities in the global drugs for schistosomiasis market.